Delivery Order SPE2DB22D9239-SPE2DB25FDK14
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on August 29, 2025, for the supply of Xenpozyme 20 mg vials. This firm fixed-price delivery order, valued at $87,418.08, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, a $500 million vehicle valid through November 2026 that enables the agency...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $87,418.08 by the Defense Logistics Agency on July 30, 2025, for the supply of Xenpozyme 20 mg vials. This firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA valued at $499,999,999 and valid through...
- The Defense Logistics Agency awarded a delivery order valued at $87,418.08 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xenpozyme 20 mg vials. The contract was awarded on September 4, 2025, with an ultimate completion date of September 25, 2025, and utilizes firm fixed-price pricing with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $87,418.08 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xenpozyme 20 mg vials. This firm fixed-price delivery order, issued on August 13, 2025, with an ultimate completion date of September 4, 2025, represents a continuation of the companies' established partnership. The award was made without a set-aside designation, allowing DMS...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $109,272.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XENPOZYME 20 MG VIALS, a specialized pharmaceutical product, with a period of performance through November 6, 2024. DMS Pharmaceutical Group is a key supplier for the DLA, holding a $499,999,999 Indefinite Delivery Contract to...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $18,488.12 on August 12, 2025, by the Defense Logistics Agency's Medical Supply Chain division. This firm fixed-price delivery order, which is scheduled for completion by August 13, 2025, represents a task order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at $499.999 billion through November...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a firm fixed-price delivery order valued at $5,021.26 from the Defense Logistics Agency's Medical Supply Chain division on September 2, 2025. The delivery order, which carries no set-aside designation, is expected to be completed by September 8, 2025, and represents a continuation of the company's ongoing pharmaceutical distribution services to Department of Defense...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,169.59 by the Defense Logistics Agency's Medical Supply Chain division on July 23, 2025. This delivery order, with an ultimate completion date of July 24, 2025, represents a single task order issued under the company's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 and valid...
- The Defense Logistics Agency awarded a delivery order valued at $201,718.80 to DMS Pharmaceutical Group Inc. for the supply of Xenpozyme 20 mg vials. This firm fixed-price delivery order, issued on September 29, 2025, is expected to be completed by October 21, 2025, with fulfillment occurring at the contractor's facility in Park Ridge, Illinois. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on equal footing despite its status as a woman-owned small...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $5,965.88 by the Defense Logistics Agency's Medical Supply Chain division on August 5, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 7, 2025, represents a continuation of the company's substantial role as a critical supplier within the federal pharmaceutical supply chain. The award carries no set-aside...
- SPE2DB22D9239Indefinite Delivery Contract
- SPE2DB22D9239-SPE2DB25FDK14Delivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on June 18, 2025, by the Defense Logistics Agency (DLA) for the supply of Xenpozyme 20 mg vials. This firm fixed-price delivery order, valued at $87,418.08, is due for completion by July 11, 2025, and represents the supply of a specialized pharmaceutical product to support Department of Defense healthcare operations. The award was issued without a set-aside designation, allowing the vendor to compete on the basis of its woman-owned small business status and established pharmaceutical distribution capabilities. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.999 billion vehicle valid through November 2026. The SPE2DB IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, biologics, and medical consumables, to support military health facilities worldwide. DMS Pharmaceutical Group's established track record of delivering specialized pharmaceutical products—ranging from oncology treatments to injectable medications—demonstrates its critical role as a pharmaceutical supplier within the federal defense supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $87.4k | 6/18/25 |